Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

SPRY1 (Sprouty Homolog 1, Antagonist Of FGF Signaling (Drosophila))

Written2013-10Behnam Nabet, Jonathan D Licht
Feinberg School of Medicine, Northwestern University, Hematology/Oncology Division, 303 East Chicago Avenue, Chicago, IL 60611-3008, USA

(Note : for Links provided by Atlas : click)

Identity

Alias_namessprouty (Drosophila) homolog 1 (antagonist of FGF signaling)
sprouty homolog 1, antagonist of FGF signaling (Drosophila)
Alias_symbol (synonym)hSPRY1
Other alias
HGNC (Hugo) SPRY1
LocusID (NCBI) 10252
Atlas_Id 51064
Location 4q28.1  [Link to chromosome band 4q28]
Location_base_pair Starts at 123396795 and ends at 123403760 bp from pter ( according to hg19-Feb_2009)  [Mapping SPRY1.png]
Fusion genes
(updated 2016)
SPRY1 (4q28.1) / SPRY1 (4q28.1)

DNA/RNA

Description SPROUTY1 (SPRY1) is located on the plus strand of chromosome 4 (124319541-124324915) and contains three exons (Figure 1A). The third exon is the coding exon.
Transcription Four transcript variants exist for SPRY1, all of which encode the same protein (according to UCSC genome browser (hg19)). Transcript variant 1 contains three exons, the last of which is the coding exon. Transcript variant 2 lacks exon 2 but retains the same coding exon as transcript variant 1. Transcript variants 3 and 4 also lack exon 2, have alternative promoters, and retain the same third coding exon (Figure 1B).

Protein

Description SPRY1 is a member of the SPRY gene family, which is composed of four genes (SPRY1, SPRY2, SPRY3, and SPRY4). SPRY1 protein is composed of 319 amino acids, which include a conserved serine-rich motif and a conserved cysteine-rich domain (Figure 1C). The C-terminal cysteine-rich domain of SPRY1 contains 23 cysteine residues, 19 of which are shared among the four family members (reviewed in Guy et al., 2009). This cysteine-rich domain facilitates homo- and heterodimer formation between SPRY proteins (Ozaki et al., 2005).
SPRY1 functions as a regulator of fundamental signaling pathways and its activity is regulated by post-translational modifications. Spry1 is phosphorylated in response to the growth factors, fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) (Mason et al., 2004). Xenopus xSpry1 is phosphorylated on the tyrosine 53 (Tyr53) residue in response to FGF treatment (Hanafusa et al., 2002). The xSpry1 Y53F mutant, which prevents this phosphorylation event, functions as a dominant-negative suggesting that phosphorylation is required for xSpry1 inhibitory activity toward growth signaling pathways (Hanafusa et al., 2002). Serine residues of Spry1 are also phosphorylated in response to FGF (Impagnatiello et al., 2001). Finally, Spry1 can be palmitoylated, and serves as a possible mechanism of membrane localization (Impagnatiello et al., 2001).
 
  Figure 1. SPROUTY1 (SPRY1) genomic context, transcript variants, and protein structure. (A) UCSC genome browser (hg19) snapshot of SPRY1 genomic context on chromosome 4q28.1. Image modified from: UCSC genome Bioinformatics. (B) UCSC genome browser (hg19) snapshot of the four SPRY1 transcripts. All transcripts retain the same coding exon. Image modified from: UCSC genome Bioinformatics. (C) Schematic of SPRY1 protein. Highlighted is the conserved N-terminal tyrosine 53 (Y53) that is phosphorylated in response to growth factor treatment, the serine-rich motif (SRM) that is phosphorylated upon growth factor treatment, and the conserved C-terminal cysteine-rich domain (CRD).
Expression Spry1 is expressed in localized domains throughout organogenesis in the developing mouse embryo and in adult tissues (Minowada et al., 1999). Spry1 is expressed during the development of the brain, salivary gland, lung, digestive tract, lens, and kidney (Minowada et al., 1999, Zhang et al., 2001, Boros et al., 2006). Notably, Spry1 is expressed in the developing mouse kidney at the condensing mesenchyme and the ureteric tree (Gross et al., 2003). During mouse embryonic development Spry1 expression patterns strongly correlate with regions of FGF expression, which may directly promote Spry1 gene activation (Minowada et al., 1999). For example, Spry1 expression is induced in response to FGF8 in explant cultures of the mouse mandibular arch (Minowada et al., 1999).
Spry1 expression is dynamically regulated in response to environmental stimuli, although the kinetics of activation vary depending on the specific cell line or stimulus used. Serum starved NIH-3T3 cells treated with FGF, PDGF, epidermal growth factor (EGF) or phorbol 12-myristate-13-acetate (PMA), upregulate Spry1 mRNA expression 30-60 minutes after stimulation (Ozaki et al., 2001). However, at time-points beyond 2 hours, Spry1 mRNA expression is downregulated in serum-starved NIH-3T3 cells treated with FGF (Gross et al., 2001). Taken together these results may reflect a transient burst of Spry1 mRNA induction in response to growth factor signaling. In mouse microvascular endothelial cells (1G11), Spry1 mRNA expression is modulated as cells are serum deprived and stimulated with FGF. Spry1 expression increases upon serum starvation, decreases after 2 hours of FGF treatment, and then increases after 6-18 hours of FGF treatment (Impagnatiello et al., 2001). Spry1 mRNA expression is increased in Th1 cells upon activation of T-cell receptor (TCR) signaling pathways (Choi et al., 2006). SPRY1 protein expression increases in U937 cells upon interferon α or β treatment (Sharma et al., 2012). Finally, SPRY1 mRNA expression increases when human umbilical vein endothelial cells (HUVECs) are subject to hypoxic conditions (Lee et al., 2010).
Spry1 activity is also regulated by transcription factors such as Wilms Tumor 1 (WT1), which binds directly to the Spry1 promoter to activate its expression (Gross et al., 2003). Furthermore, Spry1 expression is directly repressed by microRNA-21 (miR-21) (Thum et al., 2008). Importantly, miR-21 mediated repression of Spry1 leads to increased Ras-extracellular signal regulated kinase (Erk) signaling pathway activation causing cardiac fibrosis and dysfunction (Thum et al., 2008).
Localisation SPRY1 is primarily expressed in the cytoplasm and its localization to the plasma membrane is modulated upon serum deprivation and growth factor treatment. Impagnatiellio et al. demonstrated that in freely growing HUVECs, SPRY1 is localized to perinuclear and vesicular structures as well as the plasma membrane. Upon serum deprivation, SPRY1 remains cytoplasmic but is no longer detected at the plasma membrane. In response to FGF treatment, SPRY1 is again localized to the plasma membrane (Impagnatiello et al., 2001). Similarly, ectopic Spry1 in COS-1 cells translocates to membrane ruffles upon EGF treatment (Lim et al., 2002).
Function Elegant studies in Drosophila identified dSpry as a novel inhibitor of FGF and EGF signaling pathway activation during tracheal branching, oogenesis, and eye development, with specificity towards regulating the Ras-Erk cascade (Hacohen et al., 1998; Casci et al., 1999; Kramer et al., 1999; Reich et al., 1999). Similarly, subsequent studies using mammalian cell lines and mouse models revealed that SPRY1 negatively regulates receptor tyrosine kinase (RTK) signaling pathway activation in various cellular contexts. As a result, SPRY1 controls organ development and fundamental biologic processes including cell proliferation, differentiation, survival, and angiogenesis (reviewed in Mason et al., 2006; Edwin et al., 2009).
In vivo loss-of-function experiments in mice demonstrated that Spry1 is a key regulator of proper organ and tissue development. Spry1 knockout (Spry1-/-) mice have striking defects in branching morphogenesis of the kidney, develop kidney epithelial cysts, and a disease resembling the human condition known as congenital anomalies of the kidney and urinary track (Basson et al., 2005; Basson et al., 2006). Conditional deletion of Spry1 in satellite cells demonstrated that Spry1 is required for the muscle stem cell quiescence during muscle cell regeneration as well as the maintenance of muscle stem cell quiescence during ageing (Shea et al., 2010; Chakkalakal et al., 2012). Studies conditionally deleting both Spry1 and Spry2 revealed that Spry1 and Spry2 are also critical regulators of proper lens and cornea, as well as brain development. The conditional deletion of the combination of Spry1 and Spry2 results in lens and cornea defects, and cataract formation (Kuracha et al., 2011; Shin et al., 2012). Spry1 and Spry2 conditional double knockout mutants lack proper patterning of the murine brain, and altered gene expression downstream of Fgf signaling pathway activation (Faedo et al., 2010).
SPRY family members including SPRY1 function as inhibitors of Ras-Erk signaling, although the point at which SPRY inhibits pathway activation remains controversial (reviewed in Mason et al., 2006). In the developing mouse kidney, Spry1 antagonizes the glial cell line-derived neurotrophic factor (GDNF)/Ret signaling pathway to control Erk activation (Basson et al., 2005). Similarly, conditional deletion of the combination of Spry1 and Spry2 in the murine lens leads to elevated Erk activation, as well as activation of downstream FGF target genes (Kuracha et al., 2011; Shin et al., 2012). In cell lines, Spry1 regulates signaling pathway activation in response to various defined stimuli. Spry1 inhibits Ras-Erk pathway activation in response to growth factors including FGF, PDGF, and VEGF, correlating with the ability of Spry1 to control cell proliferation and differentiation (Gross et al., 2001; Impagnatiello et al., 2001). By contrast, overexpression of SPRY1 in HeLa cells leads to increased Ras-Erk pathway activation in response to EGF (Egan et al., 2002). Recent evidence demonstrates that SPRY1 is involved in inhibiting ERK and p38 MAPK activation in response to interferons, limiting expression of interferon-stimulated genes and decreasing interferon-mediated biologic responses (Sharma et al., 2012).
Growing evidence also links the SPRY family as critical regulators of phosphoinositide 3-kinase (PI3K)-protein kinase B (PKB, also known as AKT) and phospholipase C gamma (PLCγ)- protein kinase C (PKC) pathway activation. In an inner medullary collecting duct cell line, Spry1 knockdown results in enhanced and prolonged phosphorylated, activated Akt in response to GDNF treatment (Basson et al., 2006). Spry1 binds to PLCγ and inhibits PLCγ pathway activation, resulting in decreased inositol triphosphate (IP3), calcium, and diacylglycerol (DAG) production (Akbulut et al., 2010).
SPRY1 regulates TCR signaling pathway activation in a cell-type specific manner. In Th1 cells (Choi et al., 2006) and CD4+ cells (Collins et al., 2012), Spry1 inhibits signaling pathway activation, while in naïve T-cells Spry1 potentiates signaling pathway activation (Choi et al., 2006). Spry1 binds to numerous signaling intermediates including linker of activated T-cells (LAT), PLCγ1, and c-Cbl to suppress Ras-Erk, nuclear factor of activated T-cells (NFAT) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway activation (Lee et al., 2009).

Implicated in

Note
  
Entity Breast cancer
Note SPRY1 is significantly downregulated in the majority of breast cancer cases. This down-regulation was observed by comparing the expression of SPRY1 in breast cancer tumors and matched normal tissues using cDNA arrays (39/50 (78%) of paired samples) and quantitative real-time PCR (qRT-PCR) (18/19 (94%) of paired samples) (Lo et al., 2006). This data suggests that SPRY1 has tumor suppressive activity in breast cancer.
  
  
Entity Clear cell renal cell carcinoma (ccRCC)
Note Gene expression profiling of 29 ccRCC patient tumors revealed that SPRY1 expression serves as a prognostic biomarker associated with good outcome (Takahashi et al., 2001).
  
  
Entity Embryonal rhabdomyosarcoma subtype (ERMS)
Note cDNA microarray and Affymetrix microarray experiments revealed that SPRY1 mRNA expression is elevated in ERMS tumors compared to alveolar rhabdomyosarcoma subtype (RMS) tumors. Oncogenic Ras mutations leading to elevated Ras-Erk pathway activation in ERMS cell lines, result in increased SPRY1 protein expression. Inhibition of SPRY1 in ERMS cell lines decreases cell growth, survival and xenograft formation (Schaaf et al., 2010). This data suggests that in ERMS tumors driven by oncogenic Ras with elevated SPRY1 expression, targeting SPRY1 may prove to be efficacious.
  
  
Entity Glioma
Note Analysis of a glioma dataset containing expression data from 276 tumor samples revealed that SPROUTY (SPRY1, SPRY2, and SPRY4) genes are coordinately upregulated in EGFR amplified gliomas (Ivliev et al., 2010). The role and significance of SPRY1 in glioma has not been functionally addressed.
  
  
Entity Hepatocellular carcinoma
Note An initial study comparing hepatocellular carcinoma tumors with non-tumor livers, found that SPRY2 was significantly downregulated, while SPRY1 was not significantly downregulated in tumor tissue (Fong et al., 2006). qRT-PCR analysis of tissues from hepatocellular carcinoma patients revealed that SPRY1 expression levels are upregulated in 68% of patients, while SPRY2 and SPRY4 are commonly downregulated (79% and 75%, respectively). The upregulated SPRY1 levels were found in patients that did not display cirrhosis in their non-tumor tissue (Sirivatanauksorn et al., 2012). Recent evidence suggests that downregulation of SPRY1 in liver cancers occurs through miR-21 mediated repression (Jin et al., 2013).
  
  
Entity Medullary thyroid carcinoma (MTC)
Note SPRY1 has been proposed to have tumor suppressive activity in MTC. Spry1-/- mice display evidence of thyroid cell hyperplasia. Overexpression of Spry1 in an MTC cell line with low Spry1 expression reduces cell proliferation and tumor formation in xenografts through activation of the CDKN2A locus. The majority of human MTC samples tested display promoter methylation and downregulation of SPRY1 expression, in line with the proposed tumor suppressive role of SPRY1 in MTC (Macia et al., 2012).
  
  
Entity Non-small cell lung cancer (NSCLC)
Note SPRY1 mRNA expression is upregulated in NSCLC tumors compared to matched normal lung tissues, while SPRY2 mRNA expression is commonly downregulated (Sutterluty et al., 2007).
  
  
Entity Ovarian cancer
Note SPRY1 mRNA and protein expression varies in ovarian cancer cell lines. 4/7 cell lines (SKOV-3, CAOV-3, OV-90, and IGROV-1) display significantly lower SPRY1 protein expression, 1/7 cell lines (OVCAR-3) display significantly higher SPRY1 protein expression, and 2/7 cell lines (1A9 and A2780) display equivalent SPRY1 expression, as compared to normal primary human ovarian cells (Moghaddam et al., 2012).
  
  
Entity Prostate cancer
Note SPRY1 expression is downregulated in prostate cancer. This downregulation was observed by comparing prostate cancer tissue to normal tissues using immunohistochemistry (40% of 407 of paired samples) and qRT-PCR (16/20 of samples assessed) (Kwabi-Addo et al., 2004). Moderate down-regulation of SPRY1 mRNA expression was also detected in an independent study (Fritzsche et al., 2006). In addition, SPRY1 protein levels are significantly decreased in prostate cancer cell lines (LNCaP, Du145, and PC-3) compared to prostatic epithelial cell lines. Overexpression of SPRY1 in LNCaP and PC-3 cells significantly inhibits cell growth (Kwabi-Addo et al., 2004). Increased methylation of the SPRY1 promoter and miR-21 mediated repression are in part responsible for abnormal SPRY1 silencing that occurs in prostate cancer (Kwabi-Addo et al., 2009; Darimipourain et al., 2011). More recently, it was confirmed in vivo that Spry1 and Spry2 function together to inhibit prostate cancer progression (Schutzman and Martin, 2012). The conditional deletion of both Spry1 and Spry2 in mouse prostate epithelium results in ductal hyperplasia and low-grade prostatic intraepithelial neoplasia. Notably, the deletion of Spry1 and Spry2 synergizes with reduction of Pten to increase the grade and invasiveness of prostate tumorigenesis through increased PI3K-Akt and Ras-Erk signaling pathway activation (Schutzman and Martin, 2012).
  

To be noted

Acknowledgements: This work was supported by the National Institutes of Health grant CA59998 (J.D.L.) and the Lynn Sage and Northwestern Memorial Foundations (J.D.L.). B.N. is supported by a National Institutes of Health Cellular and Molecular Basis of Disease Training Grant (GM08061) and a Malkin Scholars Award from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Bibliography

Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C.
Akbulut S, Reddi AL, Aggarwal P, Ambardekar C, Canciani B, Kim MK, Hix L, Vilimas T, Mason J, Basson MA, Lovatt M, Powell J, Collins S, Quatela S, Phillips M, Licht JD.
Mol Biol Cell. 2010 Oct 1;21(19):3487-96. doi: 10.1091/mbc.E10-02-0123. Epub 2010 Aug 18.
PMID 20719962
 
Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction.
Basson MA, Akbulut S, Watson-Johnson J, Simon R, Carroll TJ, Shakya R, Gross I, Martin GR, Lufkin T, McMahon AP, Wilson PD, Costantini FD, Mason IJ, Licht JD.
Dev Cell. 2005 Feb;8(2):229-39.
PMID 15691764
 
Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1.
Basson MA, Watson-Johnson J, Shakya R, Akbulut S, Hyink D, Costantini FD, Wilson PD, Mason IJ, Licht JD.
Dev Biol. 2006 Nov 15;299(2):466-77. Epub 2006 Aug 25.
PMID 17022962
 
Sef and Sprouty expression in the developing ocular lens: implications for regulating lens cell proliferation and differentiation.
Boros J, Newitt P, Wang Q, McAvoy JW, Lovicu FJ.
Semin Cell Dev Biol. 2006 Dec;17(6):741-52. Epub 2006 Oct 26.
PMID 17141539
 
Sprouty, an intracellular inhibitor of Ras signaling.
Casci T, Vinos J, Freeman M.
Cell. 1999 Mar 5;96(5):655-65.
PMID 10089881
 
The aged niche disrupts muscle stem cell quiescence.
Chakkalakal JV, Jones KM, Basson MA, Brack AS.
Nature. 2012 Oct 18;490(7420):355-60. doi: 10.1038/nature11438. Epub 2012 Sep 26.
PMID 23023126
 
Dual effects of Sprouty1 on TCR signaling depending on the differentiation state of the T cell.
Choi H, Cho SY, Schwartz RH, Choi K.
J Immunol. 2006 May 15;176(10):6034-45.
PMID 16670312
 
Regulation of CD4^(+) and CD8^(+) effector responses by Sprouty-1.
Collins S, Waickman A, Basson A, Kupfer A, Licht JD, Horton MR, Powell JD.
PLoS One. 2012;7(11):e49801. doi: 10.1371/journal.pone.0049801. Epub 2012 Nov 15.
PMID 23166773
 
Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer.
Darimipourain M, Wang S, Ittmann M, Kwabi-Addo B.
Prostate Cancer Prostatic Dis. 2011 Dec;14(4):279-85. doi: 10.1038/pcan.2011.33. Epub 2011 Aug 9.
PMID 21826097
 
Intermolecular interactions of Sprouty proteins and their implications in development and disease.
Edwin F, Anderson K, Ying C, Patel TB.
Mol Pharmacol. 2009 Oct;76(4):679-91. doi: 10.1124/mol.109.055848. Epub 2009 Jul 1. (REVIEW)
PMID 19570949
 
The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins.
Egan JE, Hall AB, Yatsula BA, Bar-Sagi D.
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6041-6.
PMID 11983899
 
Repression of Fgf signaling by sprouty1-2 regulates cortical patterning in two distinct regions and times.
Faedo A, Borello U, Rubenstein JL.
J Neurosci. 2010 Mar 17;30(11):4015-23. doi: 10.1523/JNEUROSCI.0307-10.2010.
PMID 20237272
 
Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma.
Fong CW, Chua MS, McKie AB, Ling SH, Mason V, Li R, Yusoff P, Lo TL, Leung HY, So SK, Guy GR.
Cancer Res. 2006 Feb 15;66(4):2048-58.
PMID 16489004
 
Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma.
Fritzsche S, Kenzelmann M, Hoffmann MJ, Muller M, Engers R, Grone HJ, Schulz WA.
Endocr Relat Cancer. 2006 Sep;13(3):839-49.
PMID 16954433
 
Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation.
Gross I, Bassit B, Benezra M, Licht JD.
J Biol Chem. 2001 Dec 7;276(49):46460-8. Epub 2001 Oct 3.
PMID 11585837
 
The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development.
Gross I, Morrison DJ, Hyink DP, Georgas K, English MA, Mericskay M, Hosono S, Sassoon D, Wilson PD, Little M, Licht JD.
J Biol Chem. 2003 Oct 17;278(42):41420-30. Epub 2003 Jul 25.
PMID 12882970
 
Sprouty proteins: modified modulators, matchmakers or missing links?
Guy GR, Jackson RA, Yusoff P, Chow SY.
J Endocrinol. 2009 Nov;203(2):191-202. doi: 10.1677/JOE-09-0110. Epub 2009 May 7. (REVIEW)
PMID 19423641
 
sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways.
Hacohen N, Kramer S, Sutherland D, Hiromi Y, Krasnow MA.
Cell. 1998 Jan 23;92(2):253-63.
PMID 9458049
 
Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway.
Hanafusa H, Torii S, Yasunaga T, Nishida E.
Nat Cell Biol. 2002 Nov;4(11):850-8.
PMID 12402043
 
Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells.
Impagnatiello MA, Weitzer S, Gannon G, Compagni A, Cotten M, Christofori G.
J Cell Biol. 2001 Mar 5;152(5):1087-98.
PMID 11238463
 
Coexpression network analysis identifies transcriptional modules related to proastrocytic differentiation and sprouty signaling in glioma.
Ivliev AE, 't Hoen PA, Sergeeva MG.
Cancer Res. 2010 Dec 15;70(24):10060-70. doi: 10.1158/0008-5472.CAN-10-2465.
PMID 21159630
 
microRNA 21-mediated suppression of Sprouty1 by Pokemon affects liver cancer cell growth and proliferation.
Jin XL, Sun QS, Liu F, Yang HW, Liu M, Liu HX, Xu W, Jiang YY.
J Cell Biochem. 2013 Jul;114(7):1625-33. doi: 10.1002/jcb.24504.
PMID 23355454
 
Sprouty: a common antagonist of FGF and EGF signaling pathways in Drosophila.
Kramer S, Okabe M, Hacohen N, Krasnow MA, Hiromi Y.
Development. 1999 Jun;126(11):2515-25.
PMID 10226010
 
Spry1 and Spry2 are necessary for lens vesicle separation and corneal differentiation.
Kuracha MR, Burgess D, Siefker E, Cooper JT, Licht JD, Robinson ML, Govindarajan V.
Invest Ophthalmol Vis Sci. 2011 Aug 29;52(9):6887-97. doi: 10.1167/iovs.11-7531.
PMID 21743007
 
DNA methylation and aberrant expression of Sprouty1 in human prostate cancer.
Kwabi-Addo B, Ren C, Ittmann M.
Epigenetics. 2009 Jan;4(1):54-61. Epub 2009 Jan 20.
PMID 19164898
 
Recruitment of Sprouty1 to immune synapse regulates T cell receptor signaling.
Lee JS, Lee JE, Oh YM, Park JB, Choi H, Choi CY, Kim IH, Lee SH, Choi K.
J Immunol. 2009 Dec 1;183(11):7178-86. doi: 10.4049/jimmunol.0803799. Epub 2009 Nov 13.
PMID 19915061
 
Sprouty1 inhibits angiogenesis in association with up-regulation of p21 and p27.
Lee S, Bui Nguyen TM, Kovalenko D, Adhikari N, Grindle S, Polster SP, Friesel R, Ramakrishnan S, Hall JL.
Mol Cell Biochem. 2010 May;338(1-2):255-61. doi: 10.1007/s11010-009-0359-z. Epub 2010 Jan 7.
PMID 20054616
 
The cysteine-rich sprouty translocation domain targets mitogen-activated protein kinase inhibitory proteins to phosphatidylinositol 4,5-bisphosphate in plasma membranes.
Lim J, Yusoff P, Wong ES, Chandramouli S, Lao DH, Fong CW, Guy GR.
Mol Cell Biol. 2002 Nov;22(22):7953-66.
PMID 12391162
 
Sprouty and cancer: the first terms report.
Lo TL, Fong CW, Yusoff P, McKie AB, Chua MS, Leung HY, Guy GR.
Cancer Lett. 2006 Oct 28;242(2):141-50. Epub 2006 Feb 8. (REVIEW)
PMID 16469433
 
Sprouty1 is a candidate tumor-suppressor gene in medullary thyroid carcinoma.
Macia A, Gallel P, Vaquero M, Gou-Fabregas M, Santacana M, Maliszewska A, Robledo M, Gardiner JR, Basson MA, Matias-Guiu X, Encinas M.
Oncogene. 2012 Aug 30;31(35):3961-72. doi: 10.1038/onc.2011.556. Epub 2011 Dec 12.
PMID 22158037
 
Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling.
Mason JM, Morrison DJ, Basson MA, Licht JD.
Trends Cell Biol. 2006 Jan;16(1):45-54. Epub 2005 Dec 7. (REVIEW)
PMID 16337795
 
Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed.
Minowada G, Jarvis LA, Chi CL, Neubuser A, Sun X, Hacohen N, Krasnow MA, Martin GR.
Development. 1999 Oct;126(20):4465-75.
PMID 10498682
 
Initial report on differential expression of sprouty proteins 1 and 2 in human epithelial ovarian cancer cell lines.
Moghaddam SM, Amini A, Wei AQ, Pourgholami MH, Morris DL.
J Oncol. 2012;2012:373826. doi: 10.1155/2012/373826. Epub 2012 Nov 29.
PMID 23251157
 
ERK pathway positively regulates the expression of Sprouty genes.
Ozaki K, Kadomoto R, Asato K, Tanimura S, Itoh N, Kohno M.
Biochem Biophys Res Commun. 2001 Aug 3;285(5):1084-8.
PMID 11478764
 
Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms.
Ozaki K, Miyazaki S, Tanimura S, Kohno M.
J Cell Sci. 2005 Dec 15;118(Pt 24):5861-71.
PMID 16339969
 
Sprouty is a general inhibitor of receptor tyrosine kinase signaling.
Reich A, Sapir A, Shilo B.
Development. 1999 Sep;126(18):4139-47.
PMID 10457022
 
Silencing of SPRY1 triggers complete regression of rhabdomyosarcoma tumors carrying a mutated RAS gene.
Schaaf G, Hamdi M, Zwijnenburg D, Lakeman A, Geerts D, Versteeg R, Kool M.
Cancer Res. 2010 Jan 15;70(2):762-71. doi: 10.1158/0008-5472.CAN-09-2532. Epub 2010 Jan 12.
PMID 20068162
 
Sprouty genes function in suppression of prostate tumorigenesis.
Schutzman JL, Martin GR.
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):20023-8. doi: 10.1073/pnas.1217204109. Epub 2012 Nov 13.
PMID 23150596
 
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses.
Sharma B, Joshi S, Sassano A, Majchrzak B, Kaur S, Aggarwal P, Nabet B, Bulic M, Stein BL, McMahon B, Baker DP, Fukunaga R, Altman JK, Licht JD, Fish EN, Platanias LC.
J Biol Chem. 2012 Dec 7;287(50):42352-60. doi: 10.1074/jbc.M112.400721. Epub 2012 Oct 16.
PMID 23074222
 
Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration.
Shea KL, Xiang W, LaPorta VS, Licht JD, Keller C, Basson MA, Brack AS.
Cell Stem Cell. 2010 Feb 5;6(2):117-29. doi: 10.1016/j.stem.2009.12.015.
PMID 20144785
 
Sprouty is a negative regulator of transforming growth factor β-induced epithelial-to-mesenchymal transition and cataract.
Shin EH, Basson MA, Robinson ML, McAvoy JW, Lovicu FJ.
Mol Med. 2012 Jul 18;18:861-73. doi: 10.2119/molmed.2012.00111.
PMID 22517312
 
Differential expression of sprouty genes in hepatocellular carcinoma.
Sirivatanauksorn Y, Sirivatanauksorn V, Srisawat C, Khongmanee A, Tongkham C.
J Surg Oncol. 2012 Mar;105(3):273-6. doi: 10.1002/jso.22095. Epub 2011 Sep 19.
PMID 21932411
 
Down-regulation of Sprouty2 in non-small cell lung cancer contributes to tumor malignancy via extracellular signal-regulated kinase pathway-dependent and -independent mechanisms.
Sutterluty H, Mayer CE, Setinek U, Attems J, Ovtcharov S, Mikula M, Mikulits W, Micksche M, Berger W.
Mol Cancer Res. 2007 May;5(5):509-20.
PMID 17510316
 
Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification.
Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT.
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9. Epub 2001 Aug 7.
PMID 11493696
 
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.
Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S.
Nature. 2008 Dec 18;456(7224):980-4. doi: 10.1038/nature07511. Epub 2008 Nov 30.
PMID 19043405
 
Expression of Sprouty genes 1, 2 and 4 during mouse organogenesis.
Zhang S, Lin Y, Itaranta P, Yagi A, Vainio S.
Mech Dev. 2001 Dec;109(2):367-70.
PMID 11731251
 

Citation

This paper should be referenced as such :
Nabet, B ; Licht, JD
SPRY1 (Sprouty Homolog 1, Antagonist Of FGF Signaling (Drosophila))
Atlas Genet Cytogenet Oncol Haematol. 2014;18(5):340-345.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/SPRY1ID51064ch4q28.html


External links

Nomenclature
HGNC (Hugo)SPRY1   11269
Cards
AtlasSPRY1ID51064ch4q28
Entrez_Gene (NCBI)SPRY1  10252  sprouty RTK signaling antagonist 1
AliaseshSPRY1
GeneCards (Weizmann)SPRY1
Ensembl hg19 (Hinxton)ENSG00000164056 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000164056 [Gene_View]  chr4:123396795-123403760 [Contig_View]  SPRY1 [Vega]
ICGC DataPortalENSG00000164056
TCGA cBioPortalSPRY1
AceView (NCBI)SPRY1
Genatlas (Paris)SPRY1
WikiGenes10252
SOURCE (Princeton)SPRY1
Genetics Home Reference (NIH)SPRY1
Genomic and cartography
GoldenPath hg38 (UCSC)SPRY1  -     chr4:123396795-123403760 +  4q28.1   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)SPRY1  -     4q28.1   [Description]    (hg19-Feb_2009)
EnsemblSPRY1 - 4q28.1 [CytoView hg19]  SPRY1 - 4q28.1 [CytoView hg38]
Mapping of homologs : NCBISPRY1 [Mapview hg19]  SPRY1 [Mapview hg38]
OMIM602465   
Gene and transcription
Genbank (Entrez)AF041037 AK026960 AL602431 AV692593 AY192146
RefSeq transcript (Entrez)NM_001258038 NM_001258039 NM_005841 NM_199327
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)SPRY1
Cluster EST : UnigeneHs.744854 [ NCBI ]
CGAP (NCI)Hs.744854
Alternative Splicing GalleryENSG00000164056
Gene ExpressionSPRY1 [ NCBI-GEO ]   SPRY1 [ EBI - ARRAY_EXPRESS ]   SPRY1 [ SEEK ]   SPRY1 [ MEM ]
Gene Expression Viewer (FireBrowse)SPRY1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)10252
GTEX Portal (Tissue expression)SPRY1
Protein : pattern, domain, 3D structure
UniProt/SwissProtO43609   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtO43609  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProO43609
Splice isoforms : SwissVarO43609
PhosPhoSitePlusO43609
Domaine pattern : Prosite (Expaxy)SPR (PS51227)   
Domains : Interpro (EBI)Sprouty    SPRY1   
Domain families : Pfam (Sanger)Sprouty (PF05210)   
Domain families : Pfam (NCBI)pfam05210   
Conserved Domain (NCBI)SPRY1
DMDM Disease mutations10252
Blocks (Seattle)SPRY1
SuperfamilyO43609
Human Protein AtlasENSG00000164056
Peptide AtlasO43609
HPRD06782
IPIIPI00306505   IPI00964419   IPI00966800   IPI00967129   
Protein Interaction databases
DIP (DOE-UCLA)O43609
IntAct (EBI)O43609
FunCoupENSG00000164056
BioGRIDSPRY1
STRING (EMBL)SPRY1
ZODIACSPRY1
Ontologies - Pathways
QuickGOO43609
Ontology : AmiGOestablishment of mitotic spindle orientation  metanephros development  ureteric bud development  organ induction  protein binding  nucleoplasm  Golgi apparatus  cytosol  cytosol  cytosol  plasma membrane  negative regulation of cell proliferation  negative regulation of GTPase activity  negative regulation of fibroblast growth factor receptor signaling pathway  negative regulation of epidermal growth factor receptor signaling pathway  negative regulation of MAP kinase activity  negative regulation of Ras protein signal transduction  negative regulation of neurotrophin TRK receptor signaling pathway  bud elongation involved in lung branching  epithelial to mesenchymal transition involved in cardiac fibroblast development  negative regulation of ERK1 and ERK2 cascade  
Ontology : EGO-EBIestablishment of mitotic spindle orientation  metanephros development  ureteric bud development  organ induction  protein binding  nucleoplasm  Golgi apparatus  cytosol  cytosol  cytosol  plasma membrane  negative regulation of cell proliferation  negative regulation of GTPase activity  negative regulation of fibroblast growth factor receptor signaling pathway  negative regulation of epidermal growth factor receptor signaling pathway  negative regulation of MAP kinase activity  negative regulation of Ras protein signal transduction  negative regulation of neurotrophin TRK receptor signaling pathway  bud elongation involved in lung branching  epithelial to mesenchymal transition involved in cardiac fibroblast development  negative regulation of ERK1 and ERK2 cascade  
Pathways : BIOCARTASprouty regulation of tyrosine kinase signals [Genes]   
Pathways : KEGGJak-STAT signaling pathway   
REACTOMEO43609 [protein]
REACTOME PathwaysR-HSA-182971 [pathway]   
NDEx NetworkSPRY1
Atlas of Cancer Signalling NetworkSPRY1
Wikipedia pathwaysSPRY1
Orthology - Evolution
OrthoDB10252
GeneTree (enSembl)ENSG00000164056
Phylogenetic Trees/Animal Genes : TreeFamSPRY1
HOVERGENO43609
HOGENOMO43609
Homologs : HomoloGeneSPRY1
Homology/Alignments : Family Browser (UCSC)SPRY1
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerSPRY1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)SPRY1
dbVarSPRY1
ClinVarSPRY1
1000_GenomesSPRY1 
Exome Variant ServerSPRY1
ExAC (Exome Aggregation Consortium)SPRY1 (select the gene name)
Genetic variants : HAPMAP10252
Genomic Variants (DGV)SPRY1 [DGVbeta]
DECIPHERSPRY1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisSPRY1 
Mutations
ICGC Data PortalSPRY1 
TCGA Data PortalSPRY1 
Broad Tumor PortalSPRY1
OASIS PortalSPRY1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICSPRY1  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDSPRY1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch SPRY1
DgiDB (Drug Gene Interaction Database)SPRY1
DoCM (Curated mutations)SPRY1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)SPRY1 (select a term)
intoGenSPRY1
NCG5 (London)SPRY1
Cancer3DSPRY1(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM602465   
Orphanet
MedgenSPRY1
Genetic Testing Registry SPRY1
NextProtO43609 [Medical]
TSGene10252
GENETestsSPRY1
Target ValidationSPRY1
Huge Navigator SPRY1 [HugePedia]
snp3D : Map Gene to Disease10252
BioCentury BCIQSPRY1
ClinGenSPRY1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD10252
Chemical/Pharm GKB GenePA36098
Clinical trialSPRY1
Miscellaneous
canSAR (ICR)SPRY1 (select the gene name)
Probes
Litterature
PubMed53 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineSPRY1
EVEXSPRY1
GoPubMedSPRY1
iHOPSPRY1
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Jun 7 12:15:26 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.